Endocrine Regulations (Apr 2016)

Role of interlekin-35 as a biomarker in patients with newly diagnosed Hashimoto’s thyroiditis

  • Yilmaz Hakki,
  • Cakmak M.,
  • Ceydilek B.,
  • Demir C.,
  • Aktas A.

DOI
https://doi.org/10.1515/enr-2016-0009
Journal volume & issue
Vol. 50, no. 2
pp. 55 – 61

Abstract

Read online

Objective. Interleukin-35 (IL-35), an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-inflammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto’s thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance.

Keywords